Paper Details

  1. Home
  2. Paper Details

Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.

Author: AmeglioF, CarpanoS, CavaliereR, Di LauroL, FrascaA M, LopezM, PignattiF, RosselliM, ViciP, VitelliG

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.

Overview

The combination of DTIC + TA1 + IL-2 was active in the treatment of advanced melanoma, with acceptable toxicity. The median time to progression was 5.5 months and median survival was 11 months.
Paper Details　
Original Abstract of the Article :
BACKGROUND: DTIC and interleukin-2 (IL-2), as single agents, have a limited anti-tumor activity in patients with metastatic melanoma. Experimentally, thymosin alpha 1 (TA1) may modulate the action of IL-2. We investigated the clinical and immunological effects of a combination with these three agent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7826907

データ提供：米国国立医学図書館（NLM）

Biochemotherapy: A Multifaceted Approach to Melanoma Treatment

Melanoma, a type of skin cancer, can be particularly challenging to treat, especially in its advanced stages. This research investigates the potential of biochemotherapy, a combination of chemotherapy and biological therapies, in treating metastatic melanoma. The study explores the clinical and immunological effects of a combination therapy involving dacarbazine (DTIC), thymosin alpha 1 (TA1), and interleukin-2 (IL-2) in patients with metastatic melanoma.

Biochemotherapy Shows Promise in Melanoma Treatment

The study demonstrates the potential of biochemotherapy in treating metastatic melanoma. The study found that the combination therapy resulted in objective responses in a significant proportion of patients (36%). This suggests that biochemotherapy could be a valuable treatment option for patients with advanced melanoma, particularly those who have not responded well to other therapies. The study also found that the combination therapy was generally well-tolerated, with the majority of side effects being related to IL-2.

Exploring the Potential of Biochemotherapy

This research highlights the potential of biochemotherapy in treating metastatic melanoma. It's like using a multi-pronged approach to navigate a challenging desert—each therapy contributes to a more comprehensive and effective strategy. The study suggests that biochemotherapy could offer a valuable treatment option for patients with advanced melanoma. However, the study also acknowledges the need for further research to explore the potential of even more active regimens and to better understand the complex interactions between the various components of biochemotherapy.

Dr.Camel's Conclusion

This research provides a fascinating look at the potential of biochemotherapy in treating metastatic melanoma. It's like using a combination of strategies to navigate a challenging desert landscape—each therapy contributes to a more effective approach. The study suggests that biochemotherapy could offer a valuable treatment option for patients with advanced melanoma. It highlights the need for further research to explore the full potential of this promising approach.

Date :
  1. Date Completed 1995-02-23
  2. Date Revised 2020-02-03
Further Info :

Pubmed ID

7826907

DOI: Digital Object Identifier

S0923-7534(19)63233-3

Related Literature

Article Analysis
・Effects of dacarbazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.